Taipei, Taiwan, May 9, 2025 —Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, announced unaudited consolidated revenues of NT$2,573 million for April 2025, growing 62% month-over-month (MoM) and 24% year-over-year (YoY). Year-to-date revenues reached NT$7,303 million, representing a solid 16% YoY increase.
In April, Lotus continued to see a strong momentum across Asia, with revenues growing 19% YoY, driven by solid performance in Korea, as well as the integration of acquisitions in Thailand and Vietnam. Export markets also delivered robust results, with a 26% YoY increase, mainly driven by shipment of lenalidomide to the US. When comparing to Mar 2025, export markets grew 146% MoM, mainly due to the seasonal nature of lenalidomide revenue recognition during the beginning of each quarter.
Lotus continues to advance its specialty and oncology portfolio through strategic partnerships. On April 25, the Company signed an exclusive licensing agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialization and co-development rights of the anti-PD-1 antibody serplulimab in South Korea. Serplulimab was granted Orphan Drug Designation for ES-SCLC by Korea’s MFDS in March, reflecting the strong potential of the therapy and the effective collaboration between the two companies.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com